PharmaCyte (NASDAQ: PMCB) takes a reverse stock split to regain Nasdaq compliance
by Danessa Lincoln · The Markets DailyWhat happened
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) put a 1-for-19 reverse split of its common stock into effect on Nov. 12. The company says the split should lift the share price so it can regain compliance with the minimum bid price rule for The Nasdaq Capital Market.
Shares outstanding fall from approximately 10,755,649 as of Nov. 11 to approximately 566,087. Split-adjusted trading began at the open on Nov. 13 under the same PMCB ticker, with a new identifier for the stock.
Stockholders approved a reverse split at the March 30 annual meeting. They let the board pick a ratio between 1-for-1.1 and 1-for-100. PharmaCyte filed a certificate of amendment with the Nevada Secretary of State on Nov. 10 to set the ratio at 1-for-19.
Options, warrants and convertible securities were adjusted in proportion. Holders who would receive a fractional share get cash based on the Nov. 12 closing price, adjusted for the split. Book-entry holders need take no action.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Reverse split ratio | 1-for-19 | SEC 8-K | |
| Shares outstanding before split (as of Nov. 11, 2026) | approximately 10,755,649 | SEC 8-K press release (Exhibit 99.1) | |
| Shares outstanding after split | approximately 566,087 | SEC 8-K press release (Exhibit 99.1) | |
| Ratio range stockholders authorized | 1-for-1.1 to 1-for-100 | SEC 8-K |
Read more: PharmaCyte Biotech (PMCB) company research
Why it matters
For holders, the split changes the share count and the price per share. It does not change what the company owns or owes. Apart from fractional shares paid in cash, each holder keeps the same stake.
The total authorized share count was not reduced. The gap between shares authorized and shares outstanding is now much wider.
OptimistFi has argued that PharmaCyte's equity value is binary. It turns on whether the company revives or licenses its clinical assets and monetizes its securities holdings, or becomes a cash-constrained shell. The split addresses the listing rule and leaves that question where it was.
A reverse split rearranges the share count. It does not by itself add cash, improve operations or secure the Nasdaq listing.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
Split-adjusted trading began Nov. 13, so the share price on The Nasdaq Capital Market is the first test. A price that stays above the minimum bid requirement would support regaining compliance. A slide back below it would weaken the case.
Holders of physical stock certificates will get exchange instructions from the transfer agent, Equiniti Trust Company, LLC.
More from OptimistFi
- PMCB stock: research and coverage of PharmaCyte Biotech
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
- Weekend market prices: US stock indexes, gold and oil now
Sources
- PharmaCyte Biotech, Inc. Form 8-K — Items 3.03, 5.03 and 8.01: certificate of amendment, 1-for-19 ratio, Nov. 12 effective time and Nov. 13 start of split-adjusted trading.
- PharmaCyte Biotech, Inc. press release (Exhibit 99.1) — Nov. 11 announcement with pre-split and post-split share counts, the Nasdaq bid price purpose and fractional share treatment.
Explore OptimistFi research on PharmaCyte Biotech, Inc.: https://optimistfi.com/stocks/PMCB
Browse PharmaCyte Biotech, Inc. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the PharmaCyte Biotech, Inc. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.